Bayer CEO: AI Won't Cut Drug Development to 3 Years; Focus on Success Probability

• Bayer CEO Bill Anderson states AI won't reduce drug development timelines from 15 years to three, despite its transformative role.
• AI helps Bayer improve success probability at early stages through computational chemistry and biology for molecular design.
• Bayer avoids the competitive GLP-1 obesity drug market, focusing instead on climate-resilient agriculture and next-gen therapies.
• The company expects a turnaround by 2027, driven by restructuring, managing €30 billion debt, and new product cycles.
• Bayer's "Dynamic Shared Ownership" initiative has eliminated two-thirds of management positions to streamline decision-making.